Design and Synthesis of Orally Bioavailable 4-Methyl Heteroaryldihydropyrimidine Based Hepatitis B Virus (HBV) Capsid Inhibitors

Zongxing Qiu(Roche (China)), Guozhi Tang(National Institutes of Health), Guolong Wu(Roche (China)), Wengang Yang(Renji Hospital), A. Mayweg(Roche (Switzerland)), Zhiheng Xu(Roche (China)), Guang Yang(UNSW Sydney), Mengwei Huang(Roche (China)), Sheng Zhong(University of Illinois Urbana-Champaign), Zheng Zhou(Central China Normal University), Liping Shi(First Affiliated Hospital Zhejiang University), Hong C. Shen(Southern Medical University), Mingwei Zhou(Roche (China)), Lei Guo(Second Military Medical University), Shuang Ren(Tongji University), Wei Zhu(Roche (China)), Haixia Liu(Roche (China)), Min Jiang(Westlake University), Yi Zhang(Roche (China)), Wen-Ming Chen(Central South University), Yuxia Zhang(University of Kansas Medical Center), Weixing Zhang(Harvard University), Yi Mao(Roche (China)), Xiaoyue Wu(National Institute of Environmental Health Sciences), Hong-Xia Qiu(Roche (China)), Yongfu Liu(Guangzhou University), Xue Zhou(Roche (China)), Jim Zhen Wu, Na Qin(Tianjin University of Technology), Fang Shen(Roche (China)), Xianfeng Lin(Sir Run Run Shaw Hospital)
Journal of Medicinal Chemistry
July 26, 2016
Cited by 75


Related Papers